Combination Treatment Of Induced Pluripotent Stem Cells Using Interleukins
AssigneeSo Young Life Sciences Corporation
InventorsAvinash Seth, Nikko Lowe, Kurt Lee Brillhart
Life of this patent
Estimating the term…
Abstract
Induced pluripotent stem cells are treated using a combination of compounds that improve competence of the induced pluripotent stem cells in responding to differentiation signals and/or improve the efficiency of differentiation of the treated induced pluripotent stem cells in differentiation towards a desired phenotype. The combination treatment can incorporate two or more of prolongation of early G1 phase, treatment with an interleukin, modulation of DNA methylation, modulation of histone acetylation, and activation of the Wnt pathway. Cells derived from induced pluripotent stem cells so treated can be used in regenerative therapy and production of organoids.
Claims22
A method of generating differentiated cells from induced pluripotent stem cells (iPSCs), comprising:
- obtaining a plurality of iPSCs;
- contacting the plurality of iPSCs with a compound selected to increase duration of early G1 phase in the plurality of iPSCs;
- and
- contacting the plurality of iPSCs with an exogenous interleukin.
A composition, comprising:
- a plurality of iPSCs;
- a compound selected to increase duration of early G1 phase in the plurality of iPSCs;
- and
- an exogenous interleukin.
Dependencies are inferred from the claim text.